$4.84
+0.13 (+2.76%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ABUS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
10 interventional · 1 observational · 1 with posted results
Held by 8 tracked-famous managers (Man Group plc, CITADEL ADVISORS LLC, D. E. Shaw & Co., Inc., SUSQUEHANNA INTERNATIONAL GROUP, LLP, Squarepoint Ops LLC, +3 more) · FINRA short interest 13.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)NCT06277037observationalTo evaluate the durability of effect of imdusiran on HBV parameters | — | Recruiting | Other: Non-interventional | Long Term Follow-up | 50 | 2029-08-30 | in 1,107 d | 2024-11-27 |
| Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.NCT05960240Parts 1 and 2: Incidence of adverse events (AEs), serious AEs (SAEs), immune related AEs (irAEs) and discontinuations due to AEs and irAEs.Randomized · Single-masked · Treatment | Phase 1 | Completed | Drug: AB-101, Placebo, Nucleos(t)ide Analogue | Chronic Hepatitis b | 128 | 2025-12-04actual | — | 2026-04-13 |
| Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B InfectionNCT04980482results2026-04-29The Frequency and Severity of Treatment Emergent Adverse Events (TEAEs), Discontinuations Due to AEs and Lab Abnormalities After Dosing With AB-729 Plus Peg-IFNα-2aRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: AB-729, Peg-IFNα-2a | Chronic Hepatitis b | 43 | 2025-03-13actual | — | 2026-04-29 |
| Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV InfectionNCT06245291To evaluate the safety and tolerability of imdusiran and durvalumab in NA suppressed CHB subjectsRandomized · Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Sponsor Decision | Drug: Imdusiran, Durvalumab | Hepatitis B, Chronic | 0 | 2024-08-01actual | — | 2024-08-12 |
| Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV InfectionNCT04775797Incidence of TEAEsRandomized · Triple-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Safety | Drug: AB-836, Placebo, AB-836, Placebo, Nucleos(t)ide Analogue | Chronic Hepatitis | 110 | 2022-11-17actual | — | 2022-11-21 |
| Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue TherapyNCT02631096Frequency and severity of treatment-emergent SAEs, discontinuations due to AEs, and laboratory abnormalities, by cohort, through 28 days after the last infusion of study treatment.Randomized · Single-masked · Treatment | Phase 2 | Completed | Drug: ARB-001467 · Other: Placebo | Hepatitis B, Chronic | 36 | 2018-05-18actual | — | 2018-06-29 |
| Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular CarcinomaNCT02191878Maximum tolerated dose (MTD)Open-label · Treatment | Phase 1/2 | Completed | Drug: TKM-080301 | Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult, Liver Cell Carcinoma, Adult | 43 | May 2016actual | — | 2019-01-16 |
| A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) PatientsNCT01262235Safety and tolerability of treatment with TKM-080301Open-label · Treatment | Phase 1/2 | Completed | Drug: TKM-080301 | Cancer, Neuroendocrine Tumors, NET, Adrenocortical Carcinoma, ACC | 68 | Jul 2015actual | — | 2019-01-16 |
| Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802NCT02041715Safety and tolerability of TKM-100802Randomized · Single-masked · Treatment | Phase 1 | Terminated | Drug: TKM-100802 for Injection, Placebo | Ebola Virus Infection | 21 | Jul 2015actual | — | 2015-08-07 |
| Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 InfusionNCT01518881Safety and Tolerability of Treatment with TKM-100201Randomized · Single-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Corporate decision to reformulate the investigational product. | Drug: TKM-100201, Placebo | Ebola Virus Infection | 24 | Jul 2012actual | — | 2014-01-09 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High CholesterolNCT00927459Safety and tolerability of PRO-040201Randomized · Single-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Potential for immune stimulation to interfere with further dose escalation. | Drug: PRO-040201, Placebo | Hypercholesterolemia | 23 | Dec 2009actual | — | 2010-01-22 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19